"Chinese regulators have accepted Zai Lab’s market application for the drug KarXT, also known as xanomeline and trospium chloride, for the treatment of schizophrenia in adults.
Zai Lab has an exclusive license from Bristol-Myers’ (BMY) Karuna unit to develop and commercialize KarXT for the Chinese market, including mainland China, Taiwan, Hong Kong and Macau.
The FDA approved the drug under the brand name Cobenfy in September 2024 for the treatment of schizophrenia. Zai Lab (ZLAB) noted that Cobenfy does not have atypical antipsychotic class warnings and precautions or a boxed warning on its label, according to a statement."